Proteasome Inhibitor PS-341 (Bortezomib) Induces Calpain-dependent IκBα Degradation

Abstract

The proteasome, a key component of the ubiquitin-proteasome pathway, has emerged as an important cancer therapeutic target. PS-341 (also called Bortezomib or Velcade) is the first proteasome inhibitor approved for newly diagnosed and relapsed multiple myeloma and is currently being tested in many clinical trials against other types of cancers. One proposed mechanism by which PS-341 exerts its anticancer effect is inactivation of nuclear factor-B (NF-B) through prevention of IB␣ degradation. In this study, we show that PS-341 at concentrations that effectively inhibited the growth of human cancer cells, instead of increasing IB␣ stability, paradoxically induced IB␣ degradation. As a result, PS-341 facilitated p65 nuclear translocation and increased NF-B activity. Moreover, IB␣ degradation by PS-341 occurred early before induction of apoptosis and could not be inhibited by a pan-caspase inhibitor or caspase-8 silencing; however, it could be prevented with calpain inhibitors, calcium-chelating agents, calpain knockdown, or calpastatin overexpression. In agreement, PS-341 increased calpain activity. These data together indicate that PS-341 induces a calpain-mediated IB␣ degradation independent of caspases. In the presence of a calpain inhibitor, the apoptosis-inducing activity of PS-341 was dramatically enhanced. Collectively, these unexpected findings suggest not only a novel paradigm regarding the relationship between proteasome inhibition and NF-B activity but also a strategy to enhance the anticancer efficacy of PS-341.

Autophagy Promotes Intracellular Degradation of Type I Collagen Induced by Transforming Growth Factor (TGF)-β1

“…Interestingly, there have been several reports that proteasome inhibitors activate transcription factor NF-B in certain cell types (63)(64)(65)(66), and NF-B has been shown to inhibit Col-I ␣1 promoter activity (67).…”

Sirtuin Inhibition Induces Apoptosis-like Changes in Platelets and Thrombocytopenia

“…CalpainActivityAssay-Intracellularcalpainactivitywasmeasured as described previously (20). Washed human platelets in 96-well plates were exposed to either DMSO or sirtinol (50 and 100 M) or EX-527 (10 and 50 M) for 30 min and then loaded with t-butoxycarbonyl-Leu-Met-chloromethylcoumarin (10 M).…”

Clinical Characteristics and Treatment Results of Pediatric Relapsed/Refractory Non-Hodgkin’s Lymphomas

“…Функции протеасомы заключаются в убиквитин-зави-симой деградации белков, участвующих в процессах ангиогенеза, апоптоза, пролиферации, регуляции клеточного цикла [37]. Ингибитор протеасом бортезо-миб стали применять в лечении рецидивов ОЛЛ и НХЛ у детей с 2010 г. Механизм действия бортезомиба об-условлен блокированием протеасом и подавлением активности циклин-зависимых киназ; активацией каспазы-8; нарушением про-и антиапоптотического баланса в семействе BCL-2-белков; блокированием NF-kВ сигнального пути [38][39][40][41][42][43].…”